Suppr超能文献

环氧二十碳三烯酸的血管药理学

Vascular pharmacology of epoxyeicosatrienoic acids.

作者信息

Pfister Sandra L, Gauthier Kathryn M, Campbell William B

机构信息

Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

出版信息

Adv Pharmacol. 2010;60:27-59. doi: 10.1016/B978-0-12-385061-4.00002-7.

Abstract

Epoxyeicosatrienoic acids (EETs) are cytochrome P450 metabolites of arachidonic acid that are produced by the vascular endothelium in responses to various stimuli such as the agonists acetylcholine (ACH) or bradykinin or by shear stress which activates phospholipase A(2) to release arachidonic acid. EETs are important regulators of vascular tone and homeostasis. In the modulation of vascular tone, EETs function as endothelium-derived hyperpolarizing factors (EDHFs). In models of vascular inflammation, EETs attenuate inflammatory signaling pathways in both the endothelium and vascular smooth muscle. Likewise, EETs regulate blood vessel formation or angiogenesis by mechanisms that are still not completely understood. Soluble epoxide hydrolase (sEH) converts EETs to dihydroxyeicosatrienoic acids (DHETs) and this metabolism limits many of the biological actions of EETs. The recent development of inhibitors of sEH provides an emerging target for pharmacological manipulation of EETs. Additionally, EETs may initiate their biological effects by interacting with a cell surface protein that is a G protein-coupled receptor (GPCR). Since GPCRs represent a common target of most drugs, further characterization of the EET receptor and synthesis of specific EET agonists and antagonist can be used to exploit many of the beneficial effects of EETs in vascular diseases, such as hypertension and atherosclerosis. This review will focus on the current understanding of the contribution of EETs to the regulation of vascular tone, inflammation, and angiogenesis. Furthermore, the therapeutic potential of targeting the EET pathway in vascular disease will be highlighted.

摘要

环氧二十碳三烯酸(EETs)是花生四烯酸的细胞色素P450代谢产物,由血管内皮细胞在受到各种刺激时产生,如激动剂乙酰胆碱(ACH)或缓激肽,或由剪切应力激活磷脂酶A2释放花生四烯酸。EETs是血管张力和内环境稳态的重要调节因子。在血管张力调节中,EETs作为内皮源性超极化因子(EDHFs)发挥作用。在血管炎症模型中,EETs减弱内皮细胞和血管平滑肌中的炎症信号通路。同样,EETs通过仍未完全明确的机制调节血管形成或血管生成。可溶性环氧化物水解酶(sEH)将EETs转化为二羟基二十碳三烯酸(DHETs),这种代谢限制了EETs的许多生物学作用。sEH抑制剂的最新研发为EETs的药理学调控提供了一个新的靶点。此外,EETs可能通过与一种细胞表面蛋白相互作用来启动其生物学效应,该蛋白是一种G蛋白偶联受体(GPCR)。由于GPCRs是大多数药物的常见靶点,进一步表征EET受体以及合成特异性EET激动剂和拮抗剂可用于利用EETs在血管疾病(如高血压和动脉粥样硬化)中的许多有益作用。本综述将聚焦于目前对EETs在血管张力、炎症和血管生成调节中作用的理解。此外,还将强调靶向EET途径在血管疾病中的治疗潜力。

相似文献

1
Vascular pharmacology of epoxyeicosatrienoic acids.
Adv Pharmacol. 2010;60:27-59. doi: 10.1016/B978-0-12-385061-4.00002-7.
2
Epoxyeicosatrienoic acids and endothelium-dependent responses.
Pflugers Arch. 2010 May;459(6):881-95. doi: 10.1007/s00424-010-0804-6. Epub 2010 Mar 12.
3
Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Am J Physiol Regul Integr Comp Physiol. 2012 Feb 1;302(3):R321-30. doi: 10.1152/ajpregu.00606.2011. Epub 2011 Nov 23.
4
Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function.
Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:2-7. doi: 10.1016/j.prostaglandins.2013.01.002. Epub 2013 Jan 17.
5
Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.
Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H491-9. doi: 10.1152/ajpheart.00927.2005. Epub 2005 Oct 28.
6
Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Am J Physiol Renal Physiol. 2023 Feb 1;324(2):F138-F151. doi: 10.1152/ajprenal.00052.2022. Epub 2022 Dec 8.
8
Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.
Circ Res. 1996 Mar;78(3):415-23. doi: 10.1161/01.res.78.3.415.
9
Endothelium-independent, ouabain-sensitive relaxation of bovine coronary arteries by EETs.
Am J Physiol Heart Circ Physiol. 2001 Mar;280(3):H1113-21. doi: 10.1152/ajpheart.2001.280.3.H1113.
10
Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.
Trends Pharmacol Sci. 2007 Jan;28(1):32-8. doi: 10.1016/j.tips.2006.11.002. Epub 2006 Dec 5.

引用本文的文献

1
Endothelial dysfunction in chronic kidney disease: a clinical perspective.
Am J Physiol Heart Circ Physiol. 2025 Jul 1;329(1):H135-H153. doi: 10.1152/ajpheart.00908.2024. Epub 2025 May 27.
2
Structure-Directed Discovery of Potent Soluble Epoxide Hydrolase Inhibitors for the Treatment of Inflammatory Diseases.
J Med Chem. 2023 Feb 23;66(4):2979-3009. doi: 10.1021/acs.jmedchem.2c01996. Epub 2023 Jan 23.
4
Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury.
Adv Pharmacol. 2022;94:27-55. doi: 10.1016/bs.apha.2022.02.004. Epub 2022 Mar 30.
6
Expression and Function of Eicosanoid-Producing Cytochrome P450 Enzymes in Solid Tumors.
Front Pharmacol. 2020 Jun 9;11:828. doi: 10.3389/fphar.2020.00828. eCollection 2020.
7
New Lipid Mediators in Retinal Angiogenesis and Retinopathy.
Front Pharmacol. 2019 Jul 5;10:739. doi: 10.3389/fphar.2019.00739. eCollection 2019.
8
The arachidonic acid monooxygenase: from biochemical curiosity to physiological/pathophysiological significance.
J Lipid Res. 2018 Nov;59(11):2047-2062. doi: 10.1194/jlr.R087882. Epub 2018 Aug 28.
9
Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.
Pharmacol Ther. 2018 Dec;192:1-19. doi: 10.1016/j.pharmthera.2018.06.015. Epub 2018 Jun 30.
10
CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity.
Drug Metab Dispos. 2018 Apr;46(4):380-386. doi: 10.1124/dmd.117.078840. Epub 2018 Jan 17.

本文引用的文献

1
Epoxyeicosatrienoic acids and endothelium-dependent responses.
Pflugers Arch. 2010 May;459(6):881-95. doi: 10.1007/s00424-010-0804-6. Epub 2010 Mar 12.
2
Epoxyeicosatrienoic acid analogs and vascular function.
Curr Med Chem. 2010;17(12):1181-90. doi: 10.2174/092986710790827843.
3
Arterial stiffness is regulated by nitric oxide and endothelium-derived hyperpolarizing factor during changes in blood flow in humans.
Hypertension. 2010 Mar;55(3):674-80. doi: 10.1161/HYPERTENSIONAHA.109.142190. Epub 2010 Jan 18.
4
Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Curr Opin Pharmacol. 2010 Apr;10(2):173-8. doi: 10.1016/j.coph.2009.12.002. Epub 2010 Jan 14.
5
Soluble epoxide hydrolase inhibition modulates vascular remodeling.
Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H795-806. doi: 10.1152/ajpheart.00543.2009. Epub 2009 Dec 24.
8
Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation.
J Mol Cell Cardiol. 2010 Feb;48(2):331-41. doi: 10.1016/j.yjmcc.2009.10.022. Epub 2009 Nov 3.
9
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.
Nat Rev Drug Discov. 2009 Oct;8(10):794-805. doi: 10.1038/nrd2875.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验